BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 2537153)

  • 1. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.
    van Lohuizen M; Verbeek S; Krimpenfort P; Domen J; Saris C; Radaszkiewicz T; Berns A
    Cell; 1989 Feb; 56(4):673-82. PubMed ID: 2537153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.
    Scheijen B; Jonkers J; Acton D; Berns A
    J Virol; 1997 Jan; 71(1):9-16. PubMed ID: 8985317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
    Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
    Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice as a means to study synergism between oncogenes.
    Berns A; Breuer M; Verbeek S; van Lohuizen M
    Int J Cancer Suppl; 1989; 4():22-5. PubMed ID: 2681009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
    Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
    Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice.
    Breuer M; Slebos R; Verbeek S; van Lohuizen M; Wientjens E; Berns A
    Nature; 1989 Jul; 340(6228):61-3. PubMed ID: 2786994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MoMuLV proviral integrations identified by Sup-F selection in tumors from infected myc/pim bitransgenic mice correlate with activation of the gfi-1 gene.
    Schmidt T; Zörnig M; Beneke R; Möröy T
    Nucleic Acids Res; 1996 Jul; 24(13):2528-34. PubMed ID: 8692692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
    Yang JT; Liu CZ; Domer P; Iannaccone P
    Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.
    Shinto Y; Morimoto M; Katsumata M; Uchida A; Aozasa K; Okamoto M; Kurosawa T; Ochi T; Greene MI; Tsujimoto Y
    Oncogene; 1995 Nov; 11(9):1729-36. PubMed ID: 7478600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukaemogenesis by the delta Mo + SV Moloney murine leukaemia virus (M-MuLV) variant in E mu pim-1 transgenic mice: high frequency of recombination with a solo endogenous M-MuLV LTR in vivo.
    Suchman EL; Pattengale PK; Fan H
    J Gen Virol; 1995 Feb; 76 ( Pt 2)():347-56. PubMed ID: 7844555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoma induction by heterocyclic amines in E mu-pim-1 transgenic mice.
    Sørensen IK; Kristiansen E; Mortensen A; van Kreijl C; Adamson RH; Thorgeirsson SS
    Arch Toxicol Suppl; 1997; 19():377-86. PubMed ID: 9079225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice.
    Feldman BJ; Reid TR; Cleary ML
    Oncogene; 1997 Nov; 15(22):2735-42. PubMed ID: 9401000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2.
    Zörnig M; Schmidt T; Karsunky H; Grzeschiczek A; Möröy T
    Oncogene; 1996 Apr; 12(8):1789-801. PubMed ID: 8622900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.
    Jonkers J; Weening JJ; van der Valk M; Bobeldijk R; Berns A
    Oncogene; 1999 Oct; 18(44):5982-90. PubMed ID: 10557087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events.
    van der Houven van Oordt CW; Schouten TG; van Krieken JH; van Dierendonck JH; van der Eb AJ; Breuer ML
    Carcinogenesis; 1998 May; 19(5):847-53. PubMed ID: 9635873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated pim-1 and c-myc proto-oncogene induction in B lymphocytes from BLV-infected cows with persistent B lymphocytosis.
    Stone DM; Norton LK; Magnuson NS; Davis WC
    Leukemia; 1996 Oct; 10(10):1629-38. PubMed ID: 8847898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.
    Kroese ED; Dortant PM; van Steeg H; van Oostrom CT; van der Houven van Oordt CW; van Kranen HJ; de Vries A; Wester PW; van Kreijl CF
    Carcinogenesis; 1997 May; 18(5):975-80. PubMed ID: 9163683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas.
    Dolcetti R; Rizzo S; Viel A; Maestro R; De Re V; Feriotto G; Boiocchi M
    Oncogene; 1989 Aug; 4(8):1009-14. PubMed ID: 2548143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras.
    Breuer M; Wientjens E; Verbeek S; Slebos R; Berns A
    Cancer Res; 1991 Feb; 51(3):958-63. PubMed ID: 1988138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.